Publications by authors named "Dirk Reske"

Claim this Profile
I
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
Viktoria Galuba, Joachim Cordes, Sandra Feyerabend, Mathias Riesbeck, Eva Meisenzahl-Lechner, Dirk Reske

Schizophr Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blended-ALMAMAR app for inpatient mental health care for refugees: study protocol for a multicenter implementation study within the I-REACH consortium (Internet based REfugee mentAl healtH Care).
Isabelle Reinhardt, Laura Schmidt, Dirk Reske, Jürgen Zielasek, Gracia Braun

BMC Health Serv Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Dirk Reske

Lancet Psychiatry· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.
Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, Wolfgang Kristoferitsch, Jürgen Faiss, Dirk Reske

Biomolecules· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Dirk Reske

Eur Arch Psychiatry Clin Neurosci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis.
Hela-Felicitas Petereit, Dirk Reske, Hayrettin Tumani, Sven Jarius, F Markus Leweke

J Neurol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
Dirk Reske, Anne V Thomas, Hela-Felicitas Petereit, Gereon R Fink, Michael Schroeter

Neuroimmunomodulation· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Dirk Reske, Walter F Haupt

Expert Rev Clin Immunol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications.
Hela-Felicitas Petereit, Dirk Reske

Cerebrospinal Fluid Res· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis